Moderna (MRNA) to Release Earnings on Thursday

Moderna (NASDAQ:MRNA) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Moderna to post earnings of ($2.90) per share and revenue of $130.35 million for the quarter.

Moderna Stock Up 3.0 %

NASDAQ:MRNA opened at $26.52 on Thursday. The firm has a market capitalization of $10.25 billion, a P/E ratio of -2.86 and a beta of 2.23. Moderna has a twelve month low of $23.15 and a twelve month high of $170.47. The company has a fifty day moving average of $30.48 and a 200-day moving average of $39.07.

Wall Street Analyst Weigh In

MRNA has been the topic of several research reports. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. Morgan Stanley lowered their target price on Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. UBS Group reduced their price target on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.